Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

FDA PMA

Drug-Eluting Peripheral Transluminal Angioplasty Catheter

PMA Number: P210039 · 2022-11-04

Decision Date2022-11-04
PMA NumberP210039
Product CodeONU
Device ClassClass 3
Medical SpecialtyU
Advisory CommitteeCV

Device Summary

Drug-Eluting Peripheral Transluminal Angioplasty Catheter is a medical device manufactured by Trireme Medical, LLC. It received FDA Premarket Approval (PMA) on 2022-11-04 under PMA number P210039. The device is classified under FDA product code ONU. It was reviewed by the CV advisory panel. This device is classified as Class III by the FDA. Class III devices subject to the most stringent regulatory controls. These devices generally require premarket approval (PMA) because they support or sustain human life, are of substantial importance in preventing impairment of human health, or present a potential unreasonable risk of illness or injury. PMA is the most stringent type of device marketing application required by the FDA. The device falls under the medical specialty of U. Unlike 510(k) clearance, which demonstrates substantial equivalence to a predicate device, PMA requires the manufacturer to submit clinical trial data demonstrating the safety and effectiveness of the device. PMA is generally required for Class III devices that support or sustain human life, are of substantial importance in preventing impairment of human health, or present a potential unreasonable risk of illness or injury.

Frequently Asked Questions

What is Drug-Eluting Peripheral Transluminal Angioplasty Catheter?

Drug-Eluting Peripheral Transluminal Angioplasty Catheter is a medical device that received FDA Premarket Approval (PMA) on 2022-11-04. It is manufactured by Trireme Medical, LLC. The PMA number is P210039.

When did Drug-Eluting Peripheral Transluminal Angioplasty Catheter receive FDA PMA approval?

Drug-Eluting Peripheral Transluminal Angioplasty Catheter received FDA PMA approval on 2022-11-04, under approval number P210039.

What company makes Drug-Eluting Peripheral Transluminal Angioplasty Catheter?

Drug-Eluting Peripheral Transluminal Angioplasty Catheter is manufactured by Trireme Medical, LLC.

What is the difference between PMA and 510(k)?

PMA (Premarket Approval) is the FDA process for evaluating Class III medical devices. Unlike 510(k) clearance, which demonstrates substantial equivalence to a predicate device, PMA requires the manufacturer to provide clinical data proving safety and effectiveness. PMA is the most stringent type of device marketing application required by the FDA.

What is the FDA product code for Drug-Eluting Peripheral Transluminal Angioplasty Catheter?

The FDA product code for Drug-Eluting Peripheral Transluminal Angioplasty Catheter is ONU.

What FDA device class is Drug-Eluting Peripheral Transluminal Angioplasty Catheter?

Drug-Eluting Peripheral Transluminal Angioplasty Catheter is classified as Class III by the FDA.

Related Clinical Trials

Other Devices by Trireme Medical, LLC

Related Devices (Code: ONU)

Official Source

View on FDA Database →

Data sourced from FDA Open API. For the most current and authoritative information, always refer to the official record.